left images Contact Us
Photo Gallery
ntitle_resultsfromhumanmedic.gif
Home > Articles > Results from Human Medicine

W . BIRKMAYER, Ludwing-Boltzmann-Institute of Neurochemistry, Vienna , observed a statistically significant increase with an improvement in general health in 60% of 100 chronic neurological cases with extremely severe deficiency symptoms who were given courses of injections with Revitorgan preparations; similar results were not achieved with other geriatric preparations.

A RETT, Ludwing-Boltzmann-Institute for Research into Paediatric Brain Damage in Vienna, carried out a double-blind trial on 82 adolescents over a six months period, to study the treatment of excessive masturbation. After three injections of one ampoule of the Dilutions from pineal gland weekly, 57 patients no longer masturbated. 46 of these 82 patients have now been receiving continuous long-term treatment with one ampoule a week for two years. In 12 patients, treatment was successful with eight injections.

In 11 adolescents there was an approx. 80% reduction in the frequency of masturbation. There was no response in 2 patients. With the injected Dilutions from pineal gland, there was a characteristic effect compared with the placebo in that, depending on their particular mental power and the power of verbalization, some patients remarked on a change. There was an also noteworthy behavioral change. In the group treated with the drug there was a reduction in aggressiveness and tendency to preservation, they had a deeper and more balanced night’s sleep and their appetite and ability to work improved. There were no unpleasant side-effects under treatment with Revitorgan.

WEINMANN, Children’s Hospital of the technical University in Munich, reports a series of favorable results in convulsive disorders in children (verified objectively by EEG) in post encephalitic syndrome, in enzymopathy (phenylpyruvic acid imbecility, met chromic leucodystrophy, galactosaemia syndrome, adreno-genital syndrome, an interesting case of van Bogaert’s leucoencephalists and muscular dystrophy) (Conference reports, 1964 and seq.). Encouraging results were also reported from other University Children’s Hospitals, particularly in muscular dystrophy. Some of these results were substantiated by laboratory findings. Wunderlich, Munich and University of Mainz, provided case histories of mongoloid children from his extensive material, and these were evaluated statistically by Peter, Ulm. There were significant differences in the mental development of mongoloid children, who in addition to the conventional basic treatment, including Revitorgan-Lingual, were also given Dry Substances. The differences in the development quotient as compared with the group not treated with Dry Substances ranged from 35 to 55 (Conference report 1972).

HANDEL, previously of the children’s Hospital in Konstanz, also reported good results, particularly in convulsive disorders and mongolism, and in asthima and order allergic diseases (Conference reports 1960-1963).

H.LEHMANN, Gynaecological Dept. of Dilligen District Hospital, has obtained good therapeutic results in chronic adnexitis, pyelonephritis and infertility due to functional disorders with anovulatory cycles and from prophylactic treatment of rhesus-sensitized women with repeated incompatible pregnancies (Conference reports 1976 and following).

In the period up to 1968 HILLER, Krankenhaus der Barmherzigen Bruder, Munich, treated 332 patients with a convincingly high rate of success. There were various indications, the overwhelming majority being geriatic cases with cardiovascular disorders (Conference reports 1968).

FIORIOLI, Med. Dept., University of Innsbruck, carried out a series of tests on 40 women who had received intensive radiotherapy for gynaecological tumor. He used Revitorgan Dilutions from deciduas and was able to prevent the adverse effects of irradiation (Conference reports 1960).

BOSLA and PFAFFINGER, Munich. Hospital , Pappenheimstrabe, Munich, achieved good results in adjunctive tumor therapy and treatment of skeletal degeneration and hepatic cirrhosis (1965).

KAUTZSCH, Schwabinger Hospital, Munich, observed various effects in the treatment of liver diseases; these effects were as good as those achieved by conventional treatment. However, the treatments were not really standardized. With different treatment intervals and dosages, and so conditions were not optimal. Treatments were tolerated without complications (1962).

In 1969, W.JANSEN, Altenkrakenhaus of the City of Nuremberg, reported on his results in 111 geriatic patients. He achieved a 71% success rate (Erfahrungheilkunde No. 11/1969, P. 396 and Conference reported 1968-1972).

A.ZINNARI, F. SOLARD and V & ROMITI (Institute Nazionale di Riposo e Cura per Anziani Centre Geriatrico di Genova) reported on the potential of cytoplasmatic therapy in geriatrics, in Rassagna Geriatrica, Ancona, No.4, 4th October, 1966. 10 patients between 60 and 100 years old with cerebral sclerosis and neurological and psychiatric disorders responded well to Dil. 64”n” lipoprotein levels and pathological beta:alpha lipoprotein quotients returned to normal. The neurological picture improved in two patients with pseudobulbar syndrome with signs of pyramidal-extrapyramidal lesions. There was an improvement of neuropsychiatric clinical pictures. Three patients were completely rehabilitated. There was a marked improvement in one case of Reynaud’s disease with dystrophic cutaneous manifestations.

C.H.van RHIJN, Enschede, has repeatedly produced reports of good results in psychiatry and in the management of drug addiction (Conference reports 1967-1972).

U.DERBOLOWSKY, Hamburg, uses cytoplasmatic therapy as the basic treatment in organ neurosis.

BREZNAY, State Hospital Heviz/Hungary, compared two groups of 32 hospitalized patients receiving the same treatment (baths and physiotherapy) for degenerate locomotor disorders, myalgia, neuralgia, neuritis, rheumatism of the soft tissue, tendinopathy and bursitis. One of the two groups was given supplementary injections of Dilutions and Neydin ointments were rubbed in. there was a significant difference in the cure rate; there was a very definite improvement in 65.6% of cases receiving additional Revitorgan treatment as compared with 40.6%.

E.SCHUBERT, Eye Clinic and Outpatients Department of the techn. University of Munich, studied tolerance to Conjunctisan eye drops in 40 test subjects. There were no signs of ocular irritation whatsoever. The preparation was very well tolerated.

Between 1968 and 1972 J.FUCHS, Eye Clinic of Katharinen Hospital, Stuttgart, treated 524 patients with Conjunctisan eye drops. The indications were choroidal and retinal disorders, chronic glaucoma, previous neuroretinitis and corneal ulcers, herpes corneae and recurrent corneal erosions. 64 patients treated with Conjunctisan A and 16 patients treated with Conjunctisan A and 16 patients treated with Conjunctisan B were selected at random in order to assess the drugs. There was an objective improvement in 44 cases under the A eye drops, with little effect in 16 patients and 4 were destined to deteriorate. 14 improved under the B eye drops and remained unchanged. There were no deteriorations here. The treatment was described as effective and promising. Subconjunctival injections of Dilutions were well tolerated and again the assessments were favorable.

H.J.REUTER, Private Urological Hospital, Stuttgart, surveyed about 3000 prostate cases treated with Revitorgan preparations in the period from 1968 –1972, and about 200 patients with chron. Recurrent nephrolithiasis. Tumour patients were given concurrent THEURER multifactorial therapy, including modified immunotherapy with antibody fragments. These results are also very convincing (Peport of the Proceddings of the Deutsche Ges. F.Urologie,  21th Conference, 1965, Dusseldorf, Springer-Verlag; Der Landarzt No. 4/1965, P. 168, Erfahrungsheilkunde No. 4/1972. P. 104, Conference reports 1965 et seq.).

PAUL, Bremen, previously DRK Hospital, Bremerhaven, reported some surprising results from hospital and general practice (Der Landarzt No. 15/1972. p. 749-750 and conference reports) over a period of years.

J.Kern, Munich. Hospital Aichach /Obb., was able to measure the therapeutic effect objectively in comparative studies using cranial rheography before and after treatment with Neygeront in 25 patients (Conference reports1963). He also reports abnormal ECG findings were restored to normal.

RILLING, Stuttgart, carried out R-C-measurement, an electrophysical technique for measuring inductive and capacitative resistance. He found that Revitorgan Dilution restored normal parameters only 10 minutes after injection, wherever placebos had no effect.

SCHRAMM, Vienna, used eletro-acupuncture to measure the therapeutic results objectively.

SCHRAMM, Gengenbach, and SCHMAUSER, Mannheim, used infrared diagnosis.

WALB, Homberg, used CROHN’s electro-neural somatogram, and WOLKEWITZ, Kronberg, used cutaneous projection diagnosis (cp. Conference reports).

These finding returned to normal, paralleling the improvement also found with the SCHELLER test and the carcinochrome reaction.

FROHLICH, dental clinic of the University of Tubingen, ZAHRINGER, TRONDIE and KLOPFER achieved surprising success in cases of irritation of the dental pulp due to thermic and chemical stimuli, by injecting Revitorgan Dilutions into the gingival.

Over a period of three years ENGEL of the Dental School, Karlsruhe, treated about 400 patients for various dental indications, usually with convincing results. Disorders of the temporomandibular joint also responded well. It was possible to maintain the vitality of the pulp in many cases of root fractures (Conference reports 1965).

GERING, Dental Clinic of the University of Tubingen, reported a significant shortening of the rewarming time after cooling by injecting the Dilutions, particularly in diseases of the paradontium; this effect bears comparison with other preparations. There was a definite improvement in the severity of inflammation after the course of injections (Conference reports 1972).

Between 1963 and 1968, H.L.MICHALEK evaluated reports on 4357 cases treated with Revitorgan preparations and described in doctor’ letters. 19% were cured, and 61% showed substantial improvement. 19.2% remained unchanged. The treatment was stopped in some of these patients and so the results could not be assessed.

PETER, Ulm, collated and evaluated the therapeutic results from a further 943 patients from the period 1968 to 1971.; 521 cases were provided by 12 physicians, i.e. more than 12 case histories per physician. This corresponds to the size of a patient group from a fairly small hospital in clinical trials of drugs. There was a further 189 clinical reports from 14 physicians. The therapeutic result was assessed as very good in 416 cases 41%, as good in 475 cases = 47%, and as not so good or the result could not be assessed because the treatment had not been optimized or because the patients dropped out in 130 cases = 12% (Conference reports 1971 and 1972). No untoward side effects were reported in any of the 943 patients, but accompanying symptoms, which were not specifically being treated, did disappear.